Louis Weiner

Louis Weiner

orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2010 in Nature Reviews Immunology
Verified
Journal Article
Closed access
PDF file
Louis WeinerLouis Weiner
Louis Weiner
RSRishi Surana
Rishi Surana
SWShangzi Wang
Shangzi Wang

20 July 2020 in Antibodies
Verified
Journal Article
Open access
PDF file
DZDavid Zahavi
David Zahavi
Louis WeinerLouis Weiner
Louis Weiner
Monoclonal antibody-based immunotherapy is now considered to be a main component of cancer therapy, alongside surgery, radiation, and chemotherapy. Monoclonal antibodies possess a diverse set of clinically relevant mechanisms of action. In addition, antibodies can directly target tumor cells while simultaneously promoting the induction of long-lasting anti-tumor immune responses. The multifaceted properties of antibodies as a therapeutic platform have led to the development of new cancer treatment strategies that will have major impacts on cancer care. This review focuses on the known mechanisms of action, current clinical applications for the treatment of cancer, and mechanisms of resistance of monoclonal antibody therapy. We further discuss how monoclonal antibody-based strategies have moved towards enhancing anti-tumor immune responses by targeting immune cells instead of tumor antigens as well as some of the current combination therapies.

1 September 2020 in Cancer and Metastasis Reviews
Verified
Journal Article
Closed access
PDF file
AFAllison A. Fitzgerald
Allison A. Fitzgerald
Louis WeinerLouis Weiner
Louis Weiner

1 March 2009 in The Lancet
Verified
Journal Article
Closed access
Louis WeinerLouis Weiner
Louis Weiner
MDMadhav V Dhodapkar
Madhav V Dhodapkar
SFSoldano Ferrone
Soldano Ferrone

1 March 2012 in Cell
Verified
Journal Article
Closed access
Louis WeinerLouis Weiner
Louis Weiner
JMJoseph C. Murray
Joseph C. Murray
CSCasey W. Shuptrine
Casey W. Shuptrine

1 May 2008 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
LBLiat Binyamin
Liat Binyamin
RAR. Katherine Alpaugh
R. Katherine Alpaugh
THTracey L. Hughes
Tracey L. Hughes
CLCharles T. Lutz
Charles T. Lutz
KCKerry S. Campbell
Kerry S. Campbell
Louis WeinerLouis Weiner
Louis Weiner
Human NK cells lyse Ab-coated target cells through the process of Ab-dependent cellular cytotoxicity (ADCC). Improving ADCC responses is desirable because it is thought to be an important antitumor mechanism for some Abs. NK cell inhibitory receptors, such as killer cell Ig-like receptors, engage with MHC class I molecules on self-cells to block NK cell activation. Accordingly, we enhanced ADCC responses by blocking NK cell inhibitory receptors, thus perturbing induction of the self-recognition signal. In a cell line model of anti-lymphoma therapy, the combination of rituximab with an Ab that blocks inhibitory self-recognition yielded increased NK cell-mediated target cell lysis when compared with rituximab alone. To validate this proof-of-concept, we then used a more representative approach in which an individual’s fresh primary NK cells encountered autologous, EBV-transformed B cells. In this system, rituximab and a combination of Abs that block NK cell inhibitory receptors yielded improved NK cell-mediated lysis over rituximab alone. The results show, for the first time, that disruption of inhibitory self-recognition can efficiently promote ADCC in a human model, applying an autologous system in which physiologic checkpoints are in place. This method provides an alternative approach to potentiate the therapeutic benefit of antitumor Abs that mediate ADCC.